Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Common Variable Immunodeficiency | 6 | 2025 | 7 | 1.540 |
Why?
|
| Immunologic Deficiency Syndromes | 4 | 2024 | 75 | 1.020 |
Why?
|
| Immune System Diseases | 2 | 2025 | 20 | 1.000 |
Why?
|
| Hypertension, Portal | 2 | 2022 | 19 | 0.880 |
Why?
|
| Healthcare Disparities | 3 | 2025 | 413 | 0.830 |
Why?
|
| Nephritis, Interstitial | 1 | 2023 | 16 | 0.760 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2022 | 28 | 0.720 |
Why?
|
| Health Status Disparities | 1 | 2023 | 147 | 0.710 |
Why?
|
| Vaccines | 1 | 2023 | 97 | 0.710 |
Why?
|
| Viral Vaccines | 1 | 2022 | 56 | 0.690 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 143 | 0.660 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 94 | 0.650 |
Why?
|
| Neoplasms | 5 | 2021 | 1378 | 0.640 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 35 | 0.600 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 316 | 0.520 |
Why?
|
| Artificial Intelligence | 3 | 2025 | 216 | 0.520 |
Why?
|
| Humans | 39 | 2025 | 65845 | 0.460 |
Why?
|
| Genetic Testing | 2 | 2025 | 144 | 0.410 |
Why?
|
| Lymphocyte Activation | 2 | 2025 | 755 | 0.360 |
Why?
|
| T-Lymphocytes | 3 | 2025 | 1012 | 0.330 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2021 | 54 | 0.320 |
Why?
|
| Drug Hypersensitivity | 2 | 2020 | 28 | 0.290 |
Why?
|
| Child | 6 | 2024 | 4653 | 0.280 |
Why?
|
| Neonatal Screening | 2 | 2025 | 108 | 0.250 |
Why?
|
| CTLA-4 Antigen | 2 | 2025 | 73 | 0.240 |
Why?
|
| B-Lymphocytes | 3 | 2025 | 565 | 0.240 |
Why?
|
| Vaccination | 3 | 2023 | 388 | 0.240 |
Why?
|
| Socioeconomic Factors | 2 | 2025 | 806 | 0.230 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2024 | 27 | 0.220 |
Why?
|
| Delayed Diagnosis | 1 | 2025 | 47 | 0.220 |
Why?
|
| Antibodies, Viral | 2 | 2023 | 329 | 0.210 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2024 | 3 | 0.210 |
Why?
|
| Biomarkers | 4 | 2023 | 1503 | 0.210 |
Why?
|
| Liver Diseases | 1 | 2025 | 157 | 0.210 |
Why?
|
| Vulnerable Populations | 1 | 2025 | 95 | 0.210 |
Why?
|
| X Chromosome Inactivation | 1 | 2024 | 61 | 0.210 |
Why?
|
| Celiac Disease | 1 | 2024 | 18 | 0.200 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2023 | 282 | 0.200 |
Why?
|
| Adult | 11 | 2025 | 17579 | 0.200 |
Why?
|
| United States | 7 | 2025 | 8189 | 0.200 |
Why?
|
| Colitis, Microscopic | 1 | 2023 | 2 | 0.200 |
Why?
|
| Young Adult | 8 | 2025 | 4883 | 0.190 |
Why?
|
| Infant, Newborn | 2 | 2025 | 1439 | 0.190 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2023 | 44 | 0.190 |
Why?
|
| NF-kappa B | 1 | 2024 | 436 | 0.190 |
Why?
|
| Interferon Type I | 2 | 2021 | 198 | 0.180 |
Why?
|
| Interleukin-2 | 1 | 2023 | 168 | 0.180 |
Why?
|
| Hyperplasia | 1 | 2022 | 92 | 0.180 |
Why?
|
| Male | 16 | 2025 | 31410 | 0.180 |
Why?
|
| Hypersensitivity | 1 | 2022 | 73 | 0.180 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 80 | 0.180 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 2739 | 0.170 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2023 | 110 | 0.170 |
Why?
|
| Autoimmunity | 2 | 2020 | 250 | 0.170 |
Why?
|
| Patient Readmission | 1 | 2025 | 452 | 0.170 |
Why?
|
| Middle Aged | 12 | 2025 | 18501 | 0.170 |
Why?
|
| Hospital Mortality | 1 | 2025 | 881 | 0.160 |
Why?
|
| Adolescent | 7 | 2025 | 6368 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 50 | 0.160 |
Why?
|
| Vasculitis | 1 | 2020 | 49 | 0.160 |
Why?
|
| Germinal Center | 1 | 2020 | 40 | 0.160 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2020 | 112 | 0.150 |
Why?
|
| Immune Tolerance | 1 | 2020 | 187 | 0.150 |
Why?
|
| Hepatitis | 1 | 2020 | 58 | 0.150 |
Why?
|
| Female | 15 | 2025 | 34425 | 0.150 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 126 | 0.150 |
Why?
|
| Prevalence | 4 | 2025 | 1454 | 0.150 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 277 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2021 | 274 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2025 | 6957 | 0.140 |
Why?
|
| Disease Progression | 1 | 2023 | 1229 | 0.140 |
Why?
|
| Aged | 9 | 2025 | 15147 | 0.140 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 184 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2022 | 642 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 357 | 0.130 |
Why?
|
| Signal Transduction | 2 | 2025 | 3170 | 0.130 |
Why?
|
| Infant | 4 | 2024 | 1718 | 0.130 |
Why?
|
| Lidocaine | 1 | 2017 | 33 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 206 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.130 |
Why?
|
| Quality of Life | 1 | 2024 | 1266 | 0.130 |
Why?
|
| Anesthetics, Local | 1 | 2017 | 73 | 0.130 |
Why?
|
| Airway Management | 1 | 2017 | 60 | 0.120 |
Why?
|
| Cesarean Section | 1 | 2017 | 104 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 69 | 0.120 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 793 | 0.120 |
Why?
|
| Liver | 1 | 2020 | 875 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2024 | 1148 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 240 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1226 | 0.100 |
Why?
|
| Sweden | 2 | 2024 | 65 | 0.100 |
Why?
|
| Child, Preschool | 3 | 2024 | 2090 | 0.100 |
Why?
|
| Immunophenotyping | 2 | 2024 | 194 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2024 | 2651 | 0.090 |
Why?
|
| Risk Factors | 3 | 2025 | 5475 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2025 | 888 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 679 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 737 | 0.060 |
Why?
|
| Massachusetts | 2 | 2021 | 2158 | 0.050 |
Why?
|
| CD40 Ligand | 1 | 2025 | 159 | 0.050 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2025 | 55 | 0.050 |
Why?
|
| Heterozygote | 1 | 2024 | 175 | 0.050 |
Why?
|
| Receptors, CXCR5 | 1 | 2023 | 3 | 0.050 |
Why?
|
| Immunoglobulin D | 1 | 2023 | 9 | 0.050 |
Why?
|
| Language | 1 | 2025 | 155 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2025 | 224 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2025 | 223 | 0.050 |
Why?
|
| Fibrosis | 1 | 2023 | 172 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 40 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2024 | 178 | 0.050 |
Why?
|
| RNA, Long Noncoding | 1 | 2024 | 171 | 0.050 |
Why?
|
| Comorbidity | 1 | 2025 | 1122 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2024 | 757 | 0.040 |
Why?
|
| Health Status | 1 | 2024 | 448 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2022 | 169 | 0.040 |
Why?
|
| Desensitization, Immunologic | 1 | 2020 | 13 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2020 | 8 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2022 | 241 | 0.040 |
Why?
|
| Cytokines | 1 | 2024 | 965 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 5682 | 0.040 |
Why?
|
| Turkey | 1 | 2020 | 13 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2025 | 763 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2020 | 38 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 472 | 0.040 |
Why?
|
| Interleukin-12 | 1 | 2020 | 127 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 2020 | 101 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2020 | 52 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2020 | 186 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 603 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2025 | 1391 | 0.040 |
Why?
|
| Spleen | 1 | 2020 | 476 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2021 | 199 | 0.040 |
Why?
|
| Biopsy | 1 | 2020 | 463 | 0.030 |
Why?
|
| Inpatients | 1 | 2021 | 322 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 187 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 605 | 0.030 |
Why?
|
| Angioedema | 1 | 2017 | 11 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 1433 | 0.030 |
Why?
|
| Anaphylaxis | 1 | 2017 | 41 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 3506 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1117 | 0.030 |
Why?
|
| Lung | 1 | 2022 | 969 | 0.030 |
Why?
|
| Phenotype | 1 | 2020 | 1236 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1583 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 2790 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1198 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1793 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 691 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3340 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 1404 | 0.020 |
Why?
|
| Animals | 2 | 2024 | 21493 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 11185 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2021 | 5834 | 0.020 |
Why?
|
| Pregnancy | 1 | 2017 | 2401 | 0.020 |
Why?
|